Report - European Medicines Agency | - Sutent€¦ · BCRP. In study A6181038 the co administration of gefitinib, a BCRP inhibitor, did not result in a clinically relevant effect on the Cmax

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form